A bipartisan group of three U.S. senators are calling for more information from a Florida company that has been steadily raising the price of the cancer drug lomustine, The Wall Street Journal reported.
Sens. Susan Collins, R-Maine, Claire McCaskill, D-Mo., and Catherine Cortez Masto, D-Nev., wrote to Robert DiCrisci, the chief executive of Tri-Source Pharma LLC and CEO of NextSource Biotechnology, about the drug, the report said.
"We would like to better understand the factors contributing to the rising costs of lomustine," the group wrote in a letter, which notes the Wall Street Journal report from December that shows the price of the highest lomustine dose increasing 1,400 percent since NextSource acquired rights to the drug in 2013.
The letter calls for documents and information since 2011 about sales, profits, and expenses for the drug, and any documents the company might have regarding responses from requests from other government entities, the Journal's report said.
NextSource increased the price by 20 percent in February to about $922 per capsule, the Journal reported, citing price-data tracker Elsevier.
Bristol-Myers Squibb Co. marketed lomustine for many years and charged about $50 per capsule before the 2013 sale, the report said.
McCaskill's office reported brand-name drugs that older adults most frequently use have seen regular price increases across the past five years, with an average of 12-percent increases each year, the St. Louis Post Dispatch reported.
© 2026 Newsmax. All rights reserved.